STUDY OF MANAGEMENT OF PASIREOTIDE-INDUCED HYPERGLYCEMIA IN ADULT PATIENTS WITH CUSHING´S DISEASE OR ACROMEGALY

计划入组 11 人

A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s disease

计划入组 0 人

MAP THE SMA: a Machine-learning Based Algorithm to Predict THErapeutic Response in Spinal Muscular Atrophy

计划入组 247 人 · 首次发布于 2023 年 3 月 15 日

Pasireotide(Signifor)

C₅₈H₆₆N₁₀O₉ · Rx

liver disease program

siRNA therapeutics for ocular disease/dermatological disease (Phio Pharmaceuticals)

Rare Disease Research, LLC

CASTLEMAN DISEASE COLLABORATIVE NETWORK

United States

CURE RARE DISEASE, INC.

United States

NCI and NIDDK Initiate Phase II Trial of PentixaFor for Adrenal Tumor Subtyping

Mifepristone Shows Promise in Extending Lifespan Through Enhanced Mitophagy in Fruit Flies

Sparrow Pharmaceuticals' Clofutriben Completes Phase 2 Trial and Receives FDA Orphan Drug Designation for Cushing's Syndrome